Technical Trend Overview and Price Movement
The stock of Dr Reddys Laboratories Ltd closed at ₹1,315.70 on 11 Mar 2026, marking a 2.28% increase from the previous close of ₹1,286.40. The intraday range saw a high of ₹1,329.00 and a low of ₹1,281.90, reflecting moderate volatility within the trading session. The 52-week price range remains between ₹1,025.90 and ₹1,377.95, indicating that the current price is approaching the upper end of its annual trading band.
The technical trend has shifted from mildly bearish to sideways, signalling a potential consolidation phase after recent price movements. This transition suggests that the stock may be stabilising before a decisive directional move, a critical juncture for traders and long-term investors alike.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed signal. On a weekly basis, the MACD is bullish, indicating upward momentum in the near term. However, the monthly MACD remains mildly bearish, suggesting that longer-term momentum is still under pressure. This divergence between weekly and monthly MACD readings highlights the importance of timeframe in technical analysis and suggests that while short-term sentiment is improving, the broader trend requires cautious monitoring.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of RSI extremes implies that the stock is neither overbought nor oversold, supporting the sideways trend narrative.
Conversely, Bollinger Bands are bullish on both weekly and monthly timeframes. The price action near the upper band on these charts indicates increased volatility with a positive bias, often interpreted as a sign of potential upward breakout if sustained. This bullish stance from Bollinger Bands contrasts with the neutral RSI, suggesting that volatility may be increasing without immediate overextension.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Moving Averages and KST Indicator
Daily moving averages currently show a mildly bearish trend, indicating that short-term price averages are slightly trending downwards. This contrasts with the weekly KST (Know Sure Thing) indicator, which is mildly bullish, signalling improving momentum over the medium term. However, the monthly KST remains mildly bearish, reinforcing the mixed signals from other monthly indicators.
This divergence between daily, weekly, and monthly moving averages and momentum indicators suggests that the stock is in a transitional phase, with short-term caution balanced by some medium-term optimism.
Volume and Dow Theory Signals
On-Balance Volume (OBV) analysis shows a mildly bearish trend on the weekly chart, indicating that volume flow is not strongly supporting price advances. The monthly OBV shows no clear trend, which aligns with the sideways price action observed.
Dow Theory assessments are mildly bullish on both weekly and monthly timeframes, suggesting that the broader market sentiment for Dr Reddys Laboratories Ltd remains cautiously positive. This mild bullishness under Dow Theory may provide some support for the stock if confirmed by other technical factors.
Comparative Returns and Market Context
Dr Reddys Laboratories Ltd has outperformed the Sensex over multiple time horizons, despite recent sideways technical signals. Over the past week, the stock returned 1.63%, while the Sensex declined by 2.53%. Over one month, the stock gained 4.78% compared to a 7.20% drop in the Sensex. Year-to-date returns stand at 3.51% for the stock versus an 8.23% decline in the benchmark index.
Longer-term performance remains robust, with a 1-year return of 17.47% against the Sensex’s 5.52%, and a 3-year return of 49.63% compared to 32.25% for the Sensex. However, over five years, the stock’s 46.23% return slightly trails the Sensex’s 52.51%, and over ten years, the stock’s 106.59% gain is significantly below the Sensex’s 217.61%.
This performance profile indicates that while Dr Reddys Laboratories Ltd has delivered strong medium-term gains, it has lagged the broader market over the longest horizon, underscoring the importance of timing and sector-specific factors in investment decisions.
Why settle for Dr Reddys Laboratories Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Analyst Ratings
Dr Reddys Laboratories Ltd currently holds a Mojo Score of 48.0, which corresponds to a Mojo Grade of Sell. This represents a downgrade from the previous Hold rating on 09 Mar 2026. The downgrade reflects the mixed technical signals and cautious outlook from the MarketsMOJO analytical framework.
The company’s Market Cap Grade is 1, indicating a large-cap status but with limited momentum strength at present. The downgrade to Sell suggests that investors should exercise caution and consider the stock’s technical and fundamental factors carefully before initiating new positions.
Investment Implications and Outlook
The technical parameter changes for Dr Reddys Laboratories Ltd highlight a stock in consolidation, with short-term bullish momentum tempered by longer-term caution. The weekly bullish MACD and Bollinger Bands suggest potential for upward movement, but the mildly bearish monthly indicators and daily moving averages counsel prudence.
Investors should monitor key support and resistance levels, particularly the 52-week high of ₹1,377.95 and the recent lows near ₹1,025.90. A sustained breakout above the upper Bollinger Band and confirmation from volume indicators could signal a renewed uptrend. Conversely, failure to hold current levels may lead to further downside or extended sideways trading.
Given the current Mojo Grade downgrade to Sell, investors may prefer to wait for clearer technical confirmation or consider alternative opportunities within the Pharmaceuticals & Biotechnology sector.
Summary
Dr Reddys Laboratories Ltd is navigating a complex technical landscape characterised by a shift from mildly bearish to sideways momentum. Weekly indicators offer some bullish optimism, while monthly and daily signals remain cautious. The stock’s recent outperformance relative to the Sensex is encouraging, but the downgrade in Mojo Grade to Sell reflects underlying uncertainties. Careful analysis of technical signals and market context is essential for investors considering exposure to this pharmaceutical heavyweight.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
